1. Home
  2. SCWO vs MOLN Comparison

SCWO vs MOLN Comparison

Compare SCWO & MOLN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo 374Water Inc.

SCWO

374Water Inc.

HOLD

Current Price

$3.17

Market Cap

49.4M

Sector

Utilities

ML Signal

HOLD

Logo Molecular Partners AG

MOLN

Molecular Partners AG

N/A

Current Price

$4.20

Market Cap

170.5M

Sector

N/A

ML Signal

N/A

Company Overview

Basic Information
Metric
SCWO
MOLN
Founded
2021
2004
Country
United States
Switzerland
Employees
N/A
N/A
Industry
Environmental Services
Sector
Utilities
Exchange
Nasdaq
Nasdaq
Market Cap
49.4M
170.5M
IPO Year
2022
2021

Fundamental Metrics

Financial Performance
Metric
SCWO
MOLN
Price
$3.17
$4.20
Analyst Decision
Buy
Analyst Count
0
2
Target Price
N/A
$8.38
AVG Volume (30 Days)
56.8K
1.2K
Earning Date
05-14-2026
05-12-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
0.41
N/A
Revenue
$215,037.00
N/A
Revenue This Year
$25,798.80
N/A
Revenue Next Year
N/A
$374.07
P/E Ratio
$7.90
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.19
$3.53
52 Week High
$3.60
$5.36

Technical Indicators

Market Signals
Indicator
SCWO
MOLN
Relative Strength Index (RSI) 61.72 42.89
Support Level $2.34 $4.00
Resistance Level $3.55 $4.19
Average True Range (ATR) 0.25 0.07
MACD 0.02 -0.05
Stochastic Oscillator 66.33 1.47

Price Performance

Historical Comparison
SCWO
MOLN

About SCWO 374Water Inc.

374Water Inc is a cleantech and environmental services company developing SCWO for the destruction of organic waste streams within the municipal, federal, and industrial markets. It offers its proprietary AirSCWO technology, which is designed to efficiently destroy and mineralize a broad spectrum of non-hazardous and hazardous organic wastes producing safe dischargeable water streams, safe mineral effluent, safe vent gas, and recoverable heat energy. Its AirSCWO technology is designed to effectively convert solid and liquid wastes such as sewage sludge, biosolids, food waste, hazardous and non-hazardous waste, including forever chemicals into inert and recoverable resources including water, minerals, and heat energy.

About MOLN Molecular Partners AG

Molecular Partners AG is a clinical stage biopharmaceutical company. The Company has programs in various stages of pre-clinical and clinical development, with oncology as its main focus. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company is currently focusing on oncology through their robust pipeline of clinical and preclinical programs, with particular attention to MP0712, the key Radio-DARPin candidate targeting DLL3 now in a Phase 1/2a trial in the United States.

Share on Social Networks: